|This article relies on references to primary sources. (March 2008)|
DuBiotech, short for The Dubai Biotechnology and Research Park is a new development in Dubai aimed to attract biotechnology research and development to the emirate. Dubai Biotechnology and Research Park (DuBiotech) was officially launched by Sheikh Mohammed bin Rashid Al Maktoum, UAE Vice President and Prime Minister and Ruler of Dubai in February 2005, as part of Dubai’s 2010 vision to establish a knowledge-based economy. The Park is currently the world’s first freezone dedicated to the Life Science industry. The company is a subsidiary of the Government of Dubai's holding company, Dubai Holding. DuBiotech is also the Middle East’s first science and business park dedicated to global life science, and is a hub for fostering collaborations and innovation through its commitment to life science research, education and industry nationally and internationally.
DuBiotech, upon completion, will cover 30,000,000 square feet (2,790,000 m2) of built-up area. It is strategically located in a prime area of Dubai between the current Dubai International Airport (DXB) and the new Dubai World Central International Airport (JXB) which upon completion, will be the world's largest airport. The park is divided into zones that are dedicated to various initiatives, including research and development, manufacturing and commercial office space. Phase 1 of DuBiotech plans include DuBiotech’s Headquarters building named the 'Bio-HQ', a recent recipient of the American Institute of Architects Honor Award for Design and Sustainability, and a large scale Laboratory Complex, named 'The Nucleotide Complex', housing laboratory requirements of research oriented companies. All buildings in the park will be constructed to support the rigorous requirements of scientific research and development, and are to be LEED certified green buildings.
The mixture of incentives that DuBiotech provides creates a unique business environment for companies to start operations at the park. Besides the tax free environment, DuBiotech has already attracted key players in the pharmaceutical and biotechnology industries, as well as entrepreneurs, drug manufacturers, and industry specific business support services. DuBiotech has set up the necessary infrastructure for life science companies to conduct activities within the park including hazardous waste management, custom support services for logistics and distribution activities, and centralised facilities for research and development activities. All companies located at DuBiotech are governed by international standard regulations. Additional offerings include the future presence of a university providing graduate programs in life sciences, and BioTiqania, a continuing education institute conducting scientific training courses and certifications.
DuBiotech is actively building affiliations and alliances with distinguished universities, specialist hospitals, world regulatory bodies and other research parks to link the DuBiotech community with the global Biotechnology industry. Companies incorporated by the park or located within it are offered a unique bouquet of commercial benefits and incentives as a result of their Free Zone status.
These include: 100% foreign ownership, 100% repatriation of profits, 100% tax exemption, easy incorporation with minimal formalities, government services division (including registration, fast track immigration and customs procedures), long term land leases, guaranteed 50 years exemption from personal, income and corporate taxes, state-of-the-art IT and telecommunications infrastructure.
DuBiotech companies cover the following industry segments: Biotechnology, Medical, Industrial, Agricultural, Environmental, Equine/Animal/Marine, Pharmaceuticals, Neutraceuticals, Nanotechnology, Medical Devices, Bioinformatics, Forensic Science
Industry Activities at DuBiotech include: Diagnostics, R&D including Drug Discovery, Manufacturing, Storage, Sales & Marketing, Distribution, Consulting / Service Providers, industry specific training,CROs & Clinical Trials